Exclusive: GV-backed startup Prudentia launches with $7M to help pharma make better deals, faster

Andrew Dunn

Senior Biopharma Correspondent

Ahead of the busiest week for biopharma dealmaking at the annual JP Morgan Healthcare Conference, a new startup launched, believing its software will help prevent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: GV-backed startup Prudentia launches with $7M to help pharma make better deals, faster

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Resilience cuts 120 employees at a former bluebird gene therapy site

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Ex­clu­sive: GV-backed start­up Pru­den­tia launch­es with $7M to help phar­ma make bet­ter deals, faster

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Exclusive: GV-backed startup Prudentia launches with $7M to help pharma make better deals, faster